Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 5/20 | 0.34 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CD44 | P16070 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29051999 | 0.90 | MCL1 (0.36) | TSHRMCL1PDE2AARRAPGEF4 | |
| SCHEMBL3956006 | 0.83 | ESR1 (0.41) | TSHRMCL1PDE2AARRAPGEF4 | |
| SCHEMBL171040 | 0.82 | PDE2A (0.50) | TSHRMCL1PDE2AALDH1A1CYP1A2 | |
| SCHEMBL23913893 | 0.80 | HSD11B1 (0.41) | TSHRMCL1PDE2AARRAPGEF4 | |
| SCHEMBL25973926 | 0.80 | MCL1 (0.40) | TSHRMCL1PDE2AARRAPGEF4 | |
| SCHEMBL13105395 | 0.79 | ALDH1A1 (0.39) | TSHRPDE2ARORCALDH1A1 | |
| SCHEMBL7602705 | 0.76 | PDE2A (0.35) | TSHRMCL1PDE2AARRAPGEF4 | |
| SCHEMBL5348425 | 0.76 | MAPT (0.39) | TSHRALDH1A1CYP1A2 | |
| SCHEMBL23447265 | 0.75 | ESR1 (0.38) | TSHRMCL1PDE2AARS1PR1 | |
| SCHEMBL9912479 | 0.75 | TSHR (0.46) | TSHRMCL1ALDH1A1CYP1A2CD44 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169955-B2 | Perfluoroisopropylbenzene derivative | NIHON NOHYAKU CO., LTD. (JP) | 2007-01-30 | — | — | US | disclosed |
| US-20050113567-A1 | Perfluoroisopropylbenzene derivative | NIHON NOHYAKU CO., LTD. (JP) | 2005-05-26 | — | — | US | disclosed |
| US-20030187233-A1 | PERFLUOROISOPROPYBENZENE DERIVATIVE | NIHON NOHYAKU CO., LTD. (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1253128-A1 | PERFLUOROISOPROPYLBENZENE DERIVATIVES | Nihon Nohyaku Co., Ltd. (JP) | 2002-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187233-A1 | PERFLUOROISOPROPYBENZENE DERIVATIVE | AFF1, CBR1, RER1 | TSHR 232/4885MCL1 1851/4885PDE2A 4051/4885 |
| US-20050113567-A1 | Perfluoroisopropylbenzene derivative | FFAR3, CBR3, HCAR3 | TSHR 60/4885MCL1 3331/4885PDE2A 3361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.